Chemotherapy News and Research

Latest Chemotherapy News and Research

Study: Almost 40% of people with abnormal results ignore bowel cancer screening tests

Almost 40 per cent of people who have abnormal results from bowel cancer screening tests and are referred for further investigation ignore their next screening invitation two years later, according to a Cancer Research UK study published today (Tuesday) in the British Journal of Cancer.

7 Jan 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

6 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Brazilian researchers find that nutrition education may help prevent reoccurrence of breast cancer

Breast cancer is the most frequent cause of death among women worldwide, and five-year survival rates are just 58.4% in Brazil, lower than in many other regions. In a new study, however, researchers from Federal University of Santa Catarina provided Brazilian breast cancer patients with nutrition education and found it could benefit patients and may help prevent reoccurrence of the cancer.

6 Jan 2015

Many breast cancer patients undergoing lumpectomy surgery benefit from new intra-operative technology

Many patients undergoing lumpectomy surgery at NYU Langone Medical Center for the removal of an early detected breast tumor - the surgical option of choice for this diagnosis -- are benefitting from new intra-operative technology that detects microscopic amounts of cancer cells on removed tumor tissue not visible during or following surgical intervention.

6 Jan 2015

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

2 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.

31 Dec 2014

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients.

31 Dec 2014

OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

31 Dec 2014

New therapeutic approach shows potential for treating cancer

Case Western Reserve researchers have identified a two-pronged therapeutic approach that shows great potential for weakening and then defeating cancer cells.

31 Dec 2014

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Roche today announced that the U.S. Food and Drug Administration has provided an Emergency Use Authorization (EUA) for the LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, such as individuals traveling from West Africa.

From Roche Sequencing and Life Science 30 Dec 2014

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

The risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer remains very small, but it is twice as high as previously reported, according to results of a new study led by researchers at the Johns Hopkins Kimmel Cancer Center.

23 Dec 2014

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Myriad Genetics, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca’s drug Lynparza™ (olaparib).

22 Dec 2014

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.

19 Dec 2014

Roche announces acquisition of Bina Technologies

Roche announced today the acquisition of Bina Technologies, Inc., a privately held company based in Redwood City, California, USA. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data.

19 Dec 2014

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Study: Almost 40% of people with abnormal results ignore bowel cancer screening tests

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

EnGeneIC closes oversubscribed Series B financing

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Brazilian researchers find that nutrition education may help prevent reoccurrence of breast cancer

Many breast cancer patients undergoing lumpectomy surgery benefit from new intra-operative technology

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

OncoGenex executes initial agreement with Teva to regain rights to custirsen

New therapeutic approach shows potential for treating cancer

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Roche announces acquisition of Bina Technologies

SLU investigators find promising candidates for new herpes virus treatments

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in